.png){kind=icon}
.png){kind=icon}
Return
Mutational anc Anticenic Lancsca Tumor Procression anc Cancer Immunotheraoy
.png){kind=icon}
OA
AI
DOI：10.1016/j.tcb.2019.01.003.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expression of antigenic epitopes that can be recognized by the immune system. Since they are not covered by central tolerance, such tumor neoantigens (TNAs) should be under robust immune control as they surge. However, genetic defects that impair cancer cell eradication by the immune system coupled with the establishment of local immunosuppression can enable TNA accumulation, which is generally associated with improved clinical sensitivity to various immunotherapies. Here, we explore how tumor-intrinsic factors and immunological processes shape the mutational and antigenic landscape of evolving neoplasms to influence clinical responses to immunotherapy, and propose strategies to achieve robust immunological control of the disease despite disabled immunosurveillance.
Keywords:
IMMUNE-CHECKPOINT BLOCKADE
SQUAMOUS-CELL CARCINOMA
MHC CLASS-I
OPEN-LABEL
PD-1 BLOCKADE
LUNG-CANCER
ACQUIRED-RESISTANCE
ADVANCED MELANOMA
SINGLE-ARM
COMPREHENSIVE ANALYSIS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
18.1
Papers:
3.1K
Citations:
2.0W
Organization
View more organizations